Terns Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
TERN-701 demonstrated unprecedented efficacy and a clean safety profile in CML, outperforming current therapies, including in refractory and mutation-positive patients. Dose selection and pivotal study plans are advancing, with funding secured through commercialization.
-
The company has transitioned to focus on CML with TERN-701, showing strong efficacy and safety in third-line-plus patients, outperforming current allosteric competitors. Market opportunity is significant, with pivotal studies progressing and plans for frontline trials.
-
Promising Phase I data for TERN-701 in CML show high efficacy and favorable safety, with ongoing dose expansion and pivotal trial planning. The drug demonstrates strong differentiation from competitors, including activity against resistant mutations, and is positioned for both frontline and second-line use.
-
TERN-701 showed unprecedented efficacy and safety in refractory CML, with 75% MMR at key doses and no dose-limiting toxicities. Pivotal trials and regulatory steps are planned for 2026, supported by $1B in cash and a strong market opportunity.
Fiscal Year 2025
-
TERN-701 demonstrated unprecedented efficacy in heavily pretreated CML patients, achieving 75% MMR and 36% DMR at 24 weeks at higher doses, with a favorable safety profile and no significant pancreatic or blood pressure toxicity. These results support its potential as a best-in-disease therapy for both frontline and second-line CML.
-
Phase I data showed a 64% response rate in refractory CML with strong safety and no food effect, supporting rapid advancement to pivotal trials. The drug’s distinct profile and robust efficacy have accelerated enrollment and positioned it as a potential multi-billion dollar orphan therapy.
-
TERN-701, a next-generation allosteric BCR-ABL inhibitor, is advancing in phase I trials for CML, showing promising preclinical potency, high target coverage, and a favorable safety profile compared to asciminib. Upcoming data will benchmark efficacy and safety in a refractory patient population.
-
Upcoming data in Q4 2025 will highlight a next-generation CML therapy with superior efficacy, safety, and convenience, and an oral GLP-1 agonist for obesity with improved tolerability. Cash runway extends into 2028, supporting pivotal trials and ongoing discovery efforts.
-
The company is prioritizing its CML program, with Terns-701 showing strong safety and efficacy signals and a pivotal data readout expected in Q4 2024. The oral GLP-1 program, Terns-601, is advancing with a focus on tolerability and simplicity, with phase two data also due in Q4.
-
TERN-701 shows promise in CML with strong early efficacy, safety, and patient convenience data, with expanded results expected in Q4. TERN-601, a once-daily oral GLP-1, demonstrated up to 5.5% weight loss and favorable tolerability, with a 12-week study ongoing and a focus on business development for future commercialization.
-
Key clinical programs are advancing, with TERN-701 showing strong efficacy and safety in CML and TERN-601 demonstrating competitive weight loss and tolerability in obesity. Data readouts are expected in the second half of the year, supported by a robust cash position.
-
Two lead programs are advancing: TERN-701 for CML shows promising efficacy, safety, and convenience, with pivotal data expected in Q4, while TERN-601 for obesity demonstrated strong early weight loss and tolerability, with phase II data due later this year. Both programs are supported by a robust financial position.
-
Two lead programs, TERN-701 for CML and TERN-601 for obesity, are advancing with strong early data and significant readouts expected in 2025. TERN-701 shows promising efficacy and safety, while TERN-601 demonstrates competitive weight loss and tolerability. Over $370M in cash supports these efforts.
Fiscal Year 2024
-
Initial Phase I data for TERN-701 in heavily pretreated CML patients show a 50% MMR rate at three months, robust molecular responses, and a highly favorable safety profile with no dose-limiting toxicities. Dose expansion is set for 1H 2025, with further data expected in Q4 2025.
-
Management highlighted strong 2024 progress, including positive TERN-601 data and upcoming TERN-701 results. TERN-601 stands out for rapid titration, strong tolerability, and a differentiated PK profile, with future trials aiming for high efficacy and simplified dosing.
-
Key updates include imminent phase I data for TERN-701 in CML, with dose expansion and further readouts planned for 2025. TERN-601 showed promising phase I obesity results, with phase II starting early next year and data expected in late 2025. Cash runway extends into 2028.
-
Phase I results for TERN-601 in obesity showed up to 5.5% mean weight loss over 28 days, strong dose response, and excellent tolerability even with rapid titration. No further dose exploration is planned, and phase II is set for 2025, with combination strategies under consideration.
-
TERN-701, a next-generation allosteric BCR-ABL inhibitor, is being evaluated in a phase I study for CML patients with prior TKI failure or intolerance. Early data will focus on safety, tolerability, and individual patient efficacy signals, with differentiation based on dosing convenience and potential for improved outcomes. Six-month data will be key for future registrational decisions.
-
Key data readouts for TERN-701 in CML and TERN-601 in obesity are expected this year, with both programs emphasizing differentiation and rapid development. Allosteric inhibitors are poised to reshape CML treatment, while the obesity program targets proof-of-concept and future combinations.
-
Two major data readouts are expected in the second half of 2024, focusing on oncology and obesity. The company is confident in its CML and GLP-1 programs, emphasizing dose optimization, safety, and differentiation from competitors. Investor sentiment is turning positive ahead of these milestones.